Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy

Papillary Renal Cell Carcinoma Clinical Trial

Official title:

A Multicenter, Open, Prospective Study of Prognostic Value and Benefit From Adjuvant Immunotherapy of Stage III Papillary Renal Cell Carcinoma Based on Multi-classifier System

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06146777
• Other study ID #: FirstSunYatSen20231101
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: December 1, 2023
• Est. completion date: December 1, 2030

Study information

• Verified date: November 2023
• Source: First Affiliated Hospital, Sun Yat-Sen University
• Contact: Jun-Hang Luo, M.D.
• Phone: +862087755766
• Email: luojunh[@]mail.sysu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this trial is to test whether patients with stage III papillary renal cell carcinoma (pRCC) could benefit from adjuvant therapy or not. The investigators invented a multi-classifier system that was successfully categorise patients with stage III pRCC into high-risk and low-risk groups. Here the investigators randomly assign classifier-defined high risk patients of stage III pRCC into adjuvant pembrolizumab group placebo group. Disease-free survival and overall survival are the end points of observation.

Description:

kidney cancer represented 4.2% of all new cancer cases, and its incidence has been increasing. Over 90% of kidney cancer cases are renal cell carcinoma (RCC), which includes various subtypes with distinct histologic features, clinical courses, and responses to therapy. Clear cell renal cell carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC) are the most common histologic subtypes of RCC, accounting for approximately 75% and 20% of all cases, respectively. Adjuvant pembrolizumab showed promising efficacy in ccRCC, however, whether high-risk pRCC patients could benefit from adjuvant pembrolizumab remain unknown. Participants will be assigned to continue with the study treatment until any of the following occurs: the recurrence of the disease; the emergence of unacceptable adverse events (AEs); the presence of an intercurrent illness that precludes further administration of the treatment; the decision of the Investigator to withdraw the participant; noncompliance with the study treatment or procedural mandates; administrative reasons necessitating the discontinuation of treatment; or the completion of 17 treatment cycles (approximately one year), with each cycle 3 weeks long.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 468
• Est. completion date: December 1, 2030
• Est. primary completion date: December 1, 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Histological confirmation of pRCC
• With confirmed diagnosis of stage III pRCC
• Classified as high-risk by multi-classifier system
• With moderate/good Eastern Cooperative Oncology Group (ECOG) health rating (PS): 0-1 score.
• Receive radical operation for renal cancer with negative margin.
• Receive no anti-cancer treatment before primary surgery.
• The informed consent has been obtained from the patient.

Exclusion Criteria:

• Patients with Transcription factor enhancer 3(TFE3) or transcription factor EB (TFEB) translocation proven by cytogenetic analysis or by fluorescence in situ hybridization (FISH)
• Previously received neoadjuvant therapy
• With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.
• With bad compliance or contraindication to enrollment.
• Pregnant woman or lactating woman.
• With contraindication to receive pembrolizumab, such as had a prior solid organ transplant, has a known history of human immunodeficiency virus infection.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Renal Cell
• Papillary Renal Cell Carcinoma

Intervention

Drug:
• Pembrolizumab
Intravenous infusion
• Placebo
Intravenous infusion

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
First Affiliated Hospital, Sun Yat-Sen University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease-free survival	Disease free survival (DFS) was defined as the time interval (in years) from the date of randomization to the first date of recurrence or occurrence of a secondary malignancy or death.	From the date of registration to up to 7 years
Secondary	Overall survival	Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause.	From the date of registration to up to 7 years